论文部分内容阅读
《现代应用药学》(1992,9(2):79)刊登的“浓血液透析液的配制及其对电解质浓度调正和临床疗效观察”一文,读后认为该文在质量控制项目的设置及检验方法上存在一些问题,现讨论于下,供参考。应测定钙离子的含量测定钙镁总量并控制其在标示量的95～105%内,并不能保证钙离子的含量在标示量的95—105%内。按该文所述,血液透析液(以下简称血透液)Ⅲ号与Ⅱ号的主要差别在于钙离子浓度的不同,试制血透液Ⅳ号是为了“通过透析补充钙”“纠正患者低血钙”,说明钙离子浓度在血透液Ⅳ号中具有特殊的生理效用和临床价值;而采用甲基麝香草酚蓝(MTB)显色法或络合滴定法可以分别测定溶液中共存的钙、镁离子的含量。因此有必要也有可能单独测定血透液Ⅳ号中钙离
“Modern Applied Pharmacy” (1992,9 (2): 79) published “concentrated hemodialysis solution preparation and its electrolyte concentration adjustment and clinical efficacy observation” one article, after reading that the article set in the quality control project and test There are some problems with the method, which are discussed below for reference. Determination of calcium content Determination of calcium and magnesium total amount and control of the marked amount of 95 to 105%, and does not guarantee that the content of calcium ions within the marked amount of 95-105%. According to the article, hemodialysis fluid (hereinafter referred to as hemodialysis) Ⅲ and Ⅱ, the main difference is that the different concentrations of calcium, hemodialysis IV trial is to “supplement calcium by dialysis,” “to correct the patient’s low blood Calcium ”, indicating that the calcium concentration in the hemodialysis IV has a special physiological and clinical value; and using methyl thymol blue (MTB) colorimetric or complexometric titration can be measured in solution of coexisting calcium , Magnesium ion content. Therefore, it is also necessary and possible to measure the calcium in hemodialyzing liquid IV alone